$31.70
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
BMO Capital Initiates NewAmsterdam Pharma at Outperform With $58 Price Target
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
Overview
52-week range
$18
$42
57% of range
Avg surprise (last 3)
+25.1%
Avg reaction (last 2)
+7.2%
100% positive
Latest IV / EM
103%
EM ±23.7% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.40 | $-0.46 | +13.0% | +18.4% | +12.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.61 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.15 | $-0.52 | +71.2% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.49 | $-0.45 | -8.9% | — | +1.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.18 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.41 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.57 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.47 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$0.48 | -$0.15 | -220.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | — | $348,000 | $19M | $3M | — | $29M | $2M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-58M | — | $-55M | $-36M | $-69M | — | $-25M | $-53M |
| Net income | $-48M | — | $-72M | $-17M | $-40M | — | $-17M | $-39M |
| EPS (diluted) | $-0.40 | — | $-0.61 | $-0.15 | $-0.34 | — | $-0.18 | $-0.41 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $458M | $490M | $538M | $564M | $748M | $772M | $423M | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $658M | $676M | $732M | $770M | $817M | $863M | $438M | $445M |
| Total assets | $733M | $769M | $786M | $815M | $818M | $865M | $439M | $447M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $67M | $86M | $58M | $37M | $41M | $107M | $60M | $59M |
| Total equity | $665M | $683M | $728M | $778M | $777M | $758M | $379M | $387M |